Geron Co. (NASDAQ:GERN - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2026 EPS estimates for Geron in a research report issued on Sunday, December 8th. Leerink Partnrs analyst F. Khurshid now expects that the biopharmaceutical company will post earnings per share of $0.36 for the year, up from their previous forecast of $0.33. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Geron's current full-year earnings is ($0.25) per share.
Geron (NASDAQ:GERN - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.05. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business had revenue of $28.27 million for the quarter, compared to analyst estimates of $18.97 million. During the same quarter in the previous year, the company earned ($0.08) EPS. The company's quarterly revenue was up 17138.4% on a year-over-year basis.
Several other equities analysts also recently weighed in on GERN. HC Wainwright restated a "buy" rating and set a $9.00 target price on shares of Geron in a report on Tuesday. Barclays upgraded Geron to a "strong-buy" rating in a research report on Friday, November 29th. Scotiabank initiated coverage on Geron in a report on Wednesday, October 16th. They set a "sector outperform" rating and a $6.00 target price on the stock. Finally, Leerink Partners began coverage on Geron in a report on Monday, September 9th. They issued an "outperform" rating and a $7.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $7.15.
Check Out Our Latest Stock Report on Geron
Geron Price Performance
GERN traded down $0.01 during trading on Wednesday, reaching $3.98. 5,925,396 shares of the stock were exchanged, compared to its average volume of 10,164,946. Geron has a 1 year low of $1.64 and a 1 year high of $5.34. The company has a market capitalization of $2.41 billion, a price-to-earnings ratio of -12.47 and a beta of 0.51. The business's 50 day moving average price is $4.09 and its two-hundred day moving average price is $4.34. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74.
Hedge Funds Weigh In On Geron
Several large investors have recently added to or reduced their stakes in the business. Baader Bank Aktiengesellschaft acquired a new position in Geron in the second quarter valued at $86,000. Values First Advisors Inc. acquired a new stake in Geron during the 2nd quarter valued at $115,000. Hennion & Walsh Asset Management Inc. acquired a new stake in Geron during the 2nd quarter valued at $1,076,000. Bank of New York Mellon Corp lifted its holdings in Geron by 26.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,016,622 shares of the biopharmaceutical company's stock worth $8,550,000 after buying an additional 415,883 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Geron by 7.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 104,924 shares of the biopharmaceutical company's stock valued at $445,000 after buying an additional 7,115 shares during the last quarter. 73.71% of the stock is currently owned by hedge funds and other institutional investors.
Geron Company Profile
(
Get Free Report)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
See Also
Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.